Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 301 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CMV Clear all
Completed Phase 3 Interventional

A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis

NCT00000698
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2008 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Not applicable Interventional

A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS

NCT00002257
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Berkeley, California • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 4 Interventional Results available

Valganciclovir to Reduce T Cell Activation in HIV Infection

NCT00264290
View directory record Official record
Conditions
HIV Infections, Cytomegalovirus Infections
Interventions
Valganciclovir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 2 Interventional Results available

Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

NCT03940586
View directory record Official record
Conditions
Cytomegalovirus (CMV) Infection
Interventions
Letermovir oral granules, Letermovir tablet, Letermovir intravenous
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Duarte, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers

NCT02454699
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
MBX400, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Not applicable Interventional

A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis

NCT00002187
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Fomivirsen sodium
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Los Angeles, California • Pasadena, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

NCT05575492
View directory record Official record
Conditions
Cytomegalovirus
Interventions
mRNA-1647, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
9 Years to 25 Years
Enrollment
873 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
44
States / cities
La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor

NCT01974206
View directory record Official record
Conditions
Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Interventions
ASP0113, Placebo
Biological · Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
33
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 22, 2026, 6:00 AM EDT
Completed No phase listed Observational

PREDICT Cytomegalovirus (CMV)

NCT03300882
View directory record Official record
Conditions
Lung Transplant
Interventions
Procedure
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study

NCT00002146
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections, Hypocalcemia
Interventions
Magnesium sulfate, Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 2 Interventional

CMV Retinitis Retreatment Trial

NCT00000766
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 2Phase 3 Interventional

Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients

NCT00137748
View directory record Official record
Conditions
Hypogammaglobulinemia
Interventions
CMV-Ig
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

NCT00722839
View directory record Official record
Conditions
Nonneoplastic Condition
Interventions
PADRE-CMV fusion peptide vaccine, tetanus-CMV fusion peptide vaccine, agatolimod sodium
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 22, 2026, 6:00 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT04060277
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Letermovir, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Placebo Administration
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

NCT04017962
View directory record Official record
Conditions
CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions
Letermovir Pill, blood draw
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 4 Interventional Results available

Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection

NCT01509404
View directory record Official record
Conditions
Cytomegalovirus Disease
Interventions
Valganciclovir, CMV hyperimmune globulin
Drug · Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cytomegalovirus Vaccine in Healthy Participants

NCT00712634
View directory record Official record
Conditions
Precancerous/Nonmalignant Condition
Interventions
CMVpp65-A*0201 peptide vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2009
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2009 · Synced Oct 22, 2026, 6:00 AM EDT
Completed No phase listed Observational

Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation

NCT00170170
View directory record Official record
Conditions
Transplantation, Infection, Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus

NCT01570283
View directory record Official record
Conditions
Viral Infection
Interventions
Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 1 Interventional

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

NCT01165580
View directory record Official record
Conditions
Cytomegalovirus Infections, Heart Transplantation
Interventions
valganciclovir [Valcyte]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 124 Days
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 2 Interventional Results available

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

NCT01972035
View directory record Official record
Conditions
Transplantation Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections
Interventions
Valacyclovir, Valganciclovir
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 22, 2026, 6:00 AM EDT
Completed Phase 3 Interventional

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

NCT00006145
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 6:00 AM EDT
Recruiting Phase 1Phase 2 Interventional

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

NCT03354728
View directory record Official record
Conditions
Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient
Interventions
Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 6:00 AM EDT
Completed No phase listed Observational

The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis

NCT00341172
View directory record Official record
Conditions
AIDS
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years to 100 Years
Enrollment
2,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 22, 2026, 6:00 AM EDT